CRISPR Therapeutics to buy JV from Bayer

22-10-2019

Sarah Morgan

CRISPR Therapeutics to buy JV from Bayer

Thomas Quack / Shutterstock.com

A joint venture between gene-editing startup CRISPR Therapeutics and German pharmaceutical company Bayer will come under the control of CRISPR Therapeutics, according to the pair’s proposed plans.


Bayer, CRISPR Therapeutics, joint venture, CRISPR, gene-editing, haemophilia, ophthalmology, autoimmune diseases

LSIPR